Showing results (1-10 of 62) with videos related to
Sort By:
Pageof 7
AIDS (London, England)|February 1, 1994
Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 bindingH A Harrop, D R Coombe, C C RiderAIDS Research and Human Retroviruses|November 1, 1995
Low anticoagulant heparin retains anti-HIV type 1 activity in vitroD R Coombe, H A Harrop, J Watton, et al.Glycobiology|March 14, 1998
Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4H A Harrop, C C RiderBiochemistry|June 7, 1994
Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitroC C Rider, D R Coombe, H A Harrop, et al.Virus Research|July 7, 1999
Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytesJ Ibrahim, P Griffin, D R Coombe, et al.Leukemia & Lymphoma|May 1, 1996
The role of stromal cell heparan sulphate in regulating haemopoiesisD R CoombeCellular and Molecular Life Sciences : CMLS|February 19, 2005
Heparan sulfate-protein interactions: therapeutic potential through structure-function insightsD R Coombe, W C KettBiochemical Society Transactions|May 20, 2006
Heparin/heparan sulphate binding in the TGF-beta cytokine superfamilyC C RiderJournal of Neurochemistry|April 1, 1986
Apparent inhibition of ATP citrate lyase by L-glutamate in vitro is due to the presence of glutamine synthetaseC C RiderGlycoconjugate Journal|August 1, 1997
The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infectionC C RiderPageof 7